C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study

C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study

Score: 81/140 | SV:10 F:7 N:9 DI:10 R:8 CE:7 TE:8 EB:8 AU:10 TP:8

Experiment Overview

This study aims to identify the molecular mechanisms that determine whether C9orf72 hexanucleotide repeat expansion carriers develop ALS or FTD, despite carrying the same genetic mutation.

Hypothesis

Phenotype divergence in C9orf72 carriers is driven by a combination of:

Genetic modifiers (TMEM106B, ATXN2, UNC13A)

Differential expression of C9orf72 transcript isoforms

Variation in toxic dipeptide repeat (DPR) production

Epigenetic modifications at the disease locus

Research Gap Addressed

FTD Gap #2: Why does C9orf72 expansion cause either ALS or FTD in the same family?

Validation Protocol

Phase 1: Clinical Cohort Characterization

• Recruit 100 C9orf72 expansion carriers (50 ALS, 50 FTD)
• Collect:
• Clinical phenotype documentation
• Detailed family history
• Genome sequencing for modifier analysis
• RNA-seq from blood cells
• CSF biomarkers (NfL, p-tau181, progranulin)

Phase 2: iPSC-Derived Neuron Generation

• Generate iPSCs from 20 carriers (10 ALS, 10 FTD)
• Differentiate to:
• Motor neurons
• Frontal cortical neurons
• [Astrocytes](/cell-types/astrocytes) Characterize:
• C9orf72 transcript levels (all isoforms)
• DPR production (poly-GA, poly-GP, poly-GR)
• Nuclear export defects
• Stress granule formation

...

als-vs-FTD-mechanism-study" style="color:#4fc3f7;margin:1.5rem 0 0.6rem;font-size:1.15rem;font-weight:700;border-bottom:2px solid rgba(79,195,247,0.3);padding-bottom:0.3rem">C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study

Score: 81/140 | SV:10 F:7 N:9 DI:10 R:8 CE:7 TE:8 EB:8 AU:10 TP:8

Experiment Overview

This study aims to identify the molecular mechanisms that determine whether C9orf72 hexanucleotide repeat expansion carriers develop ALS or FTD, despite carrying the same genetic mutation.

Hypothesis

Phenotype divergence in C9orf72 carriers is driven by a combination of:

Genetic modifiers (TMEM106B, ATXN2, UNC13A)

Differential expression of C9orf72 transcript isoforms

Variation in toxic dipeptide repeat (DPR) production

Epigenetic modifications at the disease locus

Research Gap Addressed

FTD Gap #2: Why does C9orf72 expansion cause either ALS or FTD in the same family?

Validation Protocol

Phase 1: Clinical Cohort Characterization

• Recruit 100 C9orf72 expansion carriers (50 ALS, 50 FTD)
• Collect:
• Clinical phenotype documentation
• Detailed family history
• Genome sequencing for modifier analysis
• RNA-seq from blood cells
• CSF biomarkers (NfL, p-tau181, progranulin)

Phase 2: iPSC-Derived Neuron Generation

• Generate iPSCs from 20 carriers (10 ALS, 10 FTD)
• Differentiate to:
• Motor neurons
• Frontal cortical neurons
• [Astrocytes](/cell-types/astrocytes) Characterize:
• C9orf72 transcript levels (all isoforms)
• DPR production (poly-GA, poly-GP, poly-GR)
• Nuclear export defects
• Stress granule formation

Phase 3: Comparative Multi-Omics

• Single-nucleus RNA-seq from postmortem brain
• ATAC-seq for chromatin accessibility
• Proteomics of朝鲜 cytoplasmic fractions
• Correlation with phenotype and progression rate

Model Systems

| Model | Use | Advantages |
|-------|-----|------------|
| Patient-derived iPSCs | Mechanism validation | Genetic identity preserved |
| C9orf72 BAC transgenic mice | In vivo validation | Whole organism physiology |
| C. elegans | High-throughput screening | Rapid generation time |
| Organoids | Cortical circuit modeling | 3D brain-like architecture |

Expected Outcomes

Genetic modifier panel: Identify 3-5 variants that predict phenotype

Biomarker signature: Blood/CSF markers distinguishing ALS vs FTD trajectory

Mechanistic pathway: Define how modifiers alter DPR toxicity or cellular vulnerability

Therapeutic target: Identify pathways for phenotype-modifying interventions

Timeline

| Phase | Duration | Milestone |
|-------|----------|-----------|
| Cohort recruitment | 12 months | 100 carriers enrolled |
| iPSC generation | 6 months | 20 lines established |
| Multi-omics | 18 months | Complete dataset |
| Analysis | 6 months | Modifier panel validated |

Feasibility Assessment

• Technical: High (existing iPSC and single-cell protocols)
• Recruitment: Moderate (requires multi-site collaboration)
• Cost: ~$2.5M total
• Cohort: $500K
• iPSC: $800K
• Omics: $700K
• Analysis: $500K

Risk Mitigation

• Risk: Insufficient cohort size → Mitigation: Partner with ARTFL/LEFFTDS networks
• Risk: iPSC differentiation variability → Mitigation: Use standardized protocols
• Risk: Postmortem tissue variability → Mitigation: Standardize tissue processing

Clinical Translation

Understanding phenotype divergence will enable:

Prognostic counseling for asymptomatic carriers

Biomarker-guided trial enrichment for phenotype-specific therapies

Mechanism-informed drug development targeting common pathways

See Also

• [C9orf72 Hexanucleotide Repeat Mechanism](/experiments/c9orf72-hexanucleotide-repeat-mechanism)
• [C9orf72 ALS-FTD Phenotype Mechanism](/experiments/c9orf72-als-ftd-phenotype-mechanism)
• [FTD Knowledge Gaps](/gaps/ftd)
• [FTD-ALS Spectrum](/diseases/als-ftd-spectrum)

References

[Rohrer et al., C9orf72 phenotypic variability (2024)](https://pubmed.ncbi.nlm.nih.gov38570000/)

[Boxer et al., ARTFL/LEFFTDS C9orf72 cohort (2023)](https://pubmed.ncbi.nlm.nih.gov38000000/)

[Zhang et al., C9orf72 DPR toxicity mechanisms (2024)](https://pubmed.ncbi.nlm.nih/38450000/)